X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig sold 47,436 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total value of $210,615.84. Following the sale, the chairman directly owned 328,651 shares in the company, valued at $1,459,210.44. This trade represents a 12.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

X4 Pharmaceuticals Price Performance

NASDAQ XFOR remained flat at $4.29 during mid-day trading on Thursday. The company had a trading volume of 964,359 shares, compared to its average volume of 562,019. X4 Pharmaceuticals, Inc. has a 12-month low of $2.45 and a 12-month high of $4.83. The firm has a market cap of $425.35 million, a P/E ratio of -3.57 and a beta of 0.37. The stock has a 50-day moving average price of $4.04 and a 200 day moving average price of $3.96. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The firm had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $2.42 million. X4 Pharmaceuticals had a negative return on equity of 64.95% and a negative net margin of 568.80%. As a group, equities analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On X4 Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Empery Asset Management LP purchased a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at $35,804,000. Bain Capital Life Sciences Investors LLC grew its stake in X4 Pharmaceuticals by 227.0% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock worth $31,870,000 after acquiring an additional 5,530,866 shares during the period. Perceptive Advisors LLC raised its holdings in X4 Pharmaceuticals by 6.7% in the 1st quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after acquiring an additional 423,196 shares during the last quarter. Kalehua Capital Management LLC purchased a new position in shares of X4 Pharmaceuticals during the 4th quarter worth $14,891,000. Finally, Braidwell LP acquired a new stake in shares of X4 Pharmaceuticals during the fourth quarter worth $13,476,000. 72.03% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently commented on XFOR. Leerink Partners assumed coverage on shares of X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 price objective on the stock. Weiss Ratings cut shares of X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Finally, Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $11.25.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.